Description

Zabiteron Tablet 250 mg contains Abiraterone Acetate 250 mg, an oral anticancer medicine belonging to the class of androgen biosynthesis inhibitors. It is primarily used in the treatment of advanced prostate cancer, particularly in patients with metastatic prostate cancer where reducing androgen production can help slow cancer progression. Abiraterone Acetate works by inhibiting the CYP17 enzyme, which plays an important role in androgen production. By reducing androgen levels in the body, Zabiteron helps limit the growth and spread of prostate cancer cells that depend on male hormones for development. Zabiteron is generally prescribed along with corticosteroid therapy (such as prednisone/prednisolone) and is used under the supervision of an experienced oncologist. The dosage, treatment duration, and monitoring schedule depend on the patient's medical condition and response to therapy. Key Features: Contains Abiraterone Acetate 250 mg Oral hormonal therapy for advanced prostate cancer Belongs to the CYP17 inhibitor class Helps reduce androgen production supporting cancer control Used as part of comprehensive prostate cancer treatment protocols Manufactured under strict pharmaceutical quality standards Suitable for oncology hospitals, clinics, and specialty healthcare providers Therapeutic Uses: Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Castration-Sensitive Prostate Cancer (mCSPC), as recommended by an oncologist Note: Zabiteron Tablet should only be used under the direction of a qualified healthcare professional. Regular monitoring of liver function, blood pressure, potassium levels, and overall treatment response may be required during therapy.